Cerus (NASDAQ:CERS) CFO Kevin Dennis Green Sells 33,676 Shares of Stock

Cerus Corporation (NASDAQ:CERS) CFO Kevin Dennis Green sold 33,676 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $2.94, for a total value of $99,007.44. Following the transaction, the chief financial officer owned 1,062,188 shares in the company, valued at approximately $3,122,832.72. This trade represents a 3.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cerus Price Performance

Shares of NASDAQ CERS opened at $3.16 on Friday. The stock has a market capitalization of $633.17 million, a PE ratio of -63.20 and a beta of 1.77. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.63 and a quick ratio of 1.06. The business has a fifty day moving average price of $2.59 and a two-hundred day moving average price of $2.29. Cerus Corporation has a fifty-two week low of $1.15 and a fifty-two week high of $3.21.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, April 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. Cerus had a negative return on equity of 15.18% and a negative net margin of 4.41%.The company had revenue of $59.89 million for the quarter, compared to analyst estimates of $55.68 million. As a group, equities analysts predict that Cerus Corporation will post -0.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Zacks Research upgraded Cerus from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 30th. BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a report on Friday, May 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $4.00.

Hedge Funds Weigh In On Cerus

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Cerus by 0.6% in the third quarter. Vanguard Group Inc. now owns 10,783,986 shares of the biotechnology company’s stock valued at $17,147,000 after acquiring an additional 62,663 shares during the last quarter. Wasatch Advisors LP raised its position in shares of Cerus by 2.6% in the 2nd quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company’s stock worth $12,033,000 after acquiring an additional 213,917 shares in the last quarter. Senvest Management LLC lifted its stake in Cerus by 3.8% in the first quarter. Senvest Management LLC now owns 4,114,061 shares of the biotechnology company’s stock valued at $7,488,000 after buying an additional 148,812 shares during the period. Millennium Management LLC lifted its position in shares of Cerus by 17.6% during the 3rd quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock valued at $5,517,000 after acquiring an additional 519,301 shares during the period. Finally, Ieq Capital LLC increased its position in Cerus by 1.1% in the 4th quarter. Ieq Capital LLC now owns 2,423,741 shares of the biotechnology company’s stock valued at $4,993,000 after buying an additional 25,771 shares in the last quarter. 78.37% of the stock is currently owned by institutional investors.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.